Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Agenus shared a post on LinkedIn:

“Stay tuned for AACR25, where Dr. Anthony El-khoueiry will present data from our Phase 1 trial evaluating botensilimab/balstilimab in treatment-refractory hepatocellular carcinoma (HCC).

Learn more.”